Forma Therapeutics has appointed David Cook to serve as its senior vice president and chief scientific officer. Cook’s experience includes senior roles at Seres Therapeutics (NASDAQ: [[ticker:MCRB]]), the International AIDS Vaccine Initiative, Anza Therapeutics, and Cerus Corporation. Watertown, MA-based Forma develops drugs for rare blood diseases and cancers. The company’s most advanced program, olutasidenib, is currently in a pivotal study testing it as a treatment for acute myeloid leukemia.